Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil.
Johnson
M R
MR
Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Box 600, Volker Hall 101, Birmingham, AL 35294, USA.
Diasio
R B
RB
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use* / Q000633:toxicity*; D042943:Dihydrouracil Dehydrogenase (NADP); D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use* / Q000633:toxicity*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008297:Male; D010088:Oxidoreductases / Q000172:deficiency*; D010641:Phenotype
D000964:Antimetabolites, Antineoplastic; D010088:Oxidoreductases; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil